JPH07300424A - Antitumor agent composition - Google Patents

Antitumor agent composition

Info

Publication number
JPH07300424A
JPH07300424A JP6325622A JP32562294A JPH07300424A JP H07300424 A JPH07300424 A JP H07300424A JP 6325622 A JP6325622 A JP 6325622A JP 32562294 A JP32562294 A JP 32562294A JP H07300424 A JPH07300424 A JP H07300424A
Authority
JP
Japan
Prior art keywords
bamboo
cell
moss
genus
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6325622A
Other languages
Japanese (ja)
Inventor
Teruko Irie
照子 入江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOGO CO Ltd
SOGO KK
Original Assignee
SOGO CO Ltd
SOGO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOGO CO Ltd, SOGO KK filed Critical SOGO CO Ltd
Priority to JP6325622A priority Critical patent/JPH07300424A/en
Publication of JPH07300424A publication Critical patent/JPH07300424A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To obtain an antitumor agent composition showing excellent cytocydal activity and/or proliferation suppression of a tumor cell, especially a leukemia cell and an adjust T cell leukemia cell. CONSTITUTION:This antitumor agent composition is extracted from a plant belonging to a bamboo or a bamboo grass. The composition is positive in ninhydrin reaction, has about 10,000-30,000 average-molecular weight by get filtration chromatography, shows pH about 4.0-7.0, is slightly soluble in an organic solvent such as benzene or chloroform, soluble in an alcohol, an acidic or an alkaline aqueous solution and has ultraviolet light absorption approximately at 250nm (acidity) and approximately at 280nm (alkalinity) in the aqueous solution. The composition is obtained by pulverizing rhizome of a bamboo or a bamboo grass, compressing by a press, passing the pulverized rhizome and the liquid obtained in the compressing through a cloth having a rough mesh to remove a solid fiber component and a foreign matter and further filtering the filtrate by using a filter paper and/or an ultrafilter.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、抗腫瘍剤組成物に関す
る。
TECHNICAL FIELD The present invention relates to an antitumor agent composition.

【0002】[0002]

【従来の技術】現在、抗腫瘍剤としては、プラチナ錯体
及びアルキル化剤などに代表される合成物質がある。こ
れらは一般に、浸透した細胞内でDNAのグアニンと交
差−結合して殺細胞作用(抗腫瘍活性)を呈するもので
ある。
2. Description of the Related Art Currently, as antitumor agents, there are synthetic substances represented by platinum complexes and alkylating agents. These generally exhibit a cytocidal effect (antitumor activity) by cross-linking with guanine of DNA in permeated cells.

【0003】[0003]

【発明が解決する課題】抗腫瘍剤は、正常細胞との選択
性、及び殺細胞効果などの点で十分なものは得られてい
ない。現在、抗腫瘍剤の主流は合成物質であり、その活
性はDNAのグアニンと交差−結合してなる殺細胞作用
であることが多い。
As an antitumor agent, sufficient antitumor agents have not been obtained in terms of selectivity with respect to normal cells and cell killing effect. At present, the mainstream of antitumor agents are synthetic substances, and their activity is often a cytocidal effect formed by cross-bonding with guanine of DNA.

【0004】しかしながら、腫瘍の状態、種類、薬剤と
患者自身との相性、腫瘍細胞の性質、及び合併症の状態
など様々な因子が絡み、これら抗腫瘍剤は多種多様に開
発されていくことが予想され、また、その必要性があ
る。
However, various factors such as tumor state, type, compatibility between drug and patient itself, nature of tumor cell, and state of complications are involved, and these antitumor agents may be developed in various ways. It is anticipated and there is a need for it.

【0005】現在、医薬には合成新薬の他に漢方薬があ
り、それらは主に植物などの抽出物である。
At present, in addition to synthetic new medicines, there are Chinese medicines, which are mainly extracts of plants and the like.

【0006】ところで、植物の細胞内には生命維持に不
可欠の原形質とそれ以外の含有物がある。植物中から抽
出される物質としてはデンプン、脂肪粒子、炭水化物、
色素、各種の酸及び塩類(例えば、リンゴ酸、シュウ酸
カルシウム、及びマグネシウム等)、タンパク質、ホル
モン類、糖タンパク、糖類、イヌリン、ガム、タンニ
ン、アルカロイド、並びにタンパク分解酵素等が知られ
ている。これらには、代謝用の養分をあれば、老廃物も
ある。一般に、植物では老廃物が体外に排泄されずに細
胞内に溜る。従って、植物抽出物には様々な生理活性物
質が含有されていると言える。
[0006] By the way, in the cells of plants, there are protoplasms essential for life support and other contents. Substances extracted from plants include starch, fat particles, carbohydrates,
Known are pigments, various acids and salts (eg, malic acid, calcium and magnesium oxalate, etc.), proteins, hormones, glycoproteins, sugars, inulin, gums, tannins, alkaloids, and proteolytic enzymes. . These include waste products provided they have nutrients for metabolism. Generally, in plants, waste products are not excreted outside the body but accumulate in cells. Therefore, it can be said that the plant extract contains various physiologically active substances.

【0007】クマザサを始め、ササ又はタケ類は古来よ
り薬用として利用されているが、抗腫瘍剤及び抗ウイル
ス剤の用途に直接使用された例はない。
[0007] Kumazasa and other bamboo grasses or bamboos have been used for medicinal purposes since ancient times, but none have been directly used for antitumor agents and antiviral agents.

【0008】本発明者らは、タケ又はササ類から抽出し
た生理活性物質の抗腫瘍剤としての用途を検討し、新規
な抗腫瘍剤組成物を発見した。
The present inventors have investigated the use of physiologically active substances extracted from bamboo or bamboo grass as an antitumor agent, and have found a novel antitumor agent composition.

【0009】[0009]

【課題を解決するための手段】即ち、本発明は、タケ又
はササ類に属する植物より抽出され得る抗腫瘍剤組成物
であって、該組成物がニンヒドリン反応陽性、ゲルろ過
クロマトグラフィーによる平均分子量が約1万〜約3
万、約4.0〜約7.0のpHを呈し、ベンゼン及びク
ロロホルム等の有機溶剤に難溶、アルコールに可溶、ア
ルカリ性もしくは酸性の水溶液に可溶であり、該水溶液
中で紫外可視吸収を250nm付近(酸性)及び280
nm付近(アルカリ性)に有することを特徴とする抗腫
瘍剤組成物である。
[Means for Solving the Problems] That is, the present invention provides an antitumor agent composition that can be extracted from a plant belonging to bamboo or bamboo grass, wherein the composition has a positive ninhydrin reaction and an average molecular weight by gel filtration chromatography. Is about 10,000 to about 3
It exhibits a pH of about 4.0 to about 7.0, is sparingly soluble in organic solvents such as benzene and chloroform, soluble in alcohol, soluble in alkaline or acidic aqueous solutions, and absorbs UV-visible light in the aqueous solutions. Around 250 nm (acidic) and 280
The antitumor agent composition is characterized in that it has a wavelength in the vicinity of nm (alkaline).

【0010】本発明の組成物をタケ類又はササ類から抽
出する方法は、任意の方法で行うことができる。
The method of extracting the composition of the present invention from bamboos or bamboo grasses can be performed by any method.

【0011】例えば、先ずその根茎部を細砕する。この
細砕には通常の方法ならどのような方法をも適用でき
る。即ち、包丁の背で叩く、などがあるが、泡立ちの防
止及び空気中の酸素との接触時間を最小限に抑える等を
考慮して、プレス機を用いて圧搾するのが好ましい。細
砕した根茎部及び圧搾の際に得られる液体を、例えばガ
ーゼなどの目付の荒い布を通して固形の繊維分及び異物
などを除去し、更に、ろ紙及び/又は限外ろ過器を用い
てろ過することによって本発明の組成物が得られる。こ
の抽出液1ml当たりの蒸発残留物は、約0.1〜約1
mgである。
For example, first, the rhizome is crushed. Any ordinary method can be applied to this crushing. That is, although it may be hit with the back of a kitchen knife, it is preferable to use a pressing machine in consideration of prevention of foaming and minimizing the contact time with oxygen in the air. The finely ground rhizomes and the liquid obtained at the time of pressing are filtered through a rough cloth such as gauze to remove solid fiber components and foreign substances, and further filtered using a filter paper and / or an ultrafilter. Thus, the composition of the present invention is obtained. The evaporation residue per 1 ml of this extract is about 0.1 to about 1
mg.

【0012】あるいは、本発明の組成物は、タケ類又は
ササ類を有機溶媒、例えばアルコール、好ましくはメタ
ノール又はエタノールで抽出し、その後溶媒を留去する
ことによっても得ることができる。このとき、組成物は
淡黄色固体又はアメ状物の形態で得られる。
Alternatively, the composition of the present invention can be obtained by extracting bamboos or bamboo grass with an organic solvent such as alcohol, preferably methanol or ethanol, and then distilling off the solvent. The composition is then obtained in the form of a pale yellow solid or candy.

【0013】本発明の組成物は、更に精製して使用する
ことも可能である。このような精製方法としては、ゲル
ろ過法を含むクロマトグラフィー、電気泳動、透析、限
外ろ過、塩析及び有機溶剤による沈殿処理が挙げられる
がこの限りではない。
The composition of the present invention can be further purified before use. Such purification methods include, but are not limited to, chromatography including gel filtration, electrophoresis, dialysis, ultrafiltration, salting out, and precipitation with an organic solvent.

【0014】より具体的には、クロマトグラフィーとし
ては、例えば、デキストラン又はポリアクリルアミド又
はアルミナなどを充填したカラムによるクロマトグラフ
ィーが挙げられる。
More specifically, examples of the chromatography include chromatography with a column packed with dextran or polyacrylamide or alumina.

【0015】透析としては、例えば、コロジオン膜及び
セロファン膜等の半透膜を用いた透析が挙げられる。
Examples of dialysis include dialysis using a semipermeable membrane such as a collodion membrane and a cellophane membrane.

【0016】限外ろ過としては、例えば、無機質及び樹
脂製の多孔質膜を用いたろ過が挙げられる。
Examples of the ultrafiltration include filtration using a porous membrane made of an inorganic material and a resin.

【0017】塩析用の凝集剤としては、例えば、硫酸ア
ンモニウム、塩化ナトリウム及び炭酸バリウム等が、有
機溶剤による沈殿処理には、例えば、メタノール、エタ
ノール及びアセトン等が用いられ得るが、本発明の組成
物中の有効成分を変性させない条件で行うことが好まし
い。
As the aggregating agent for salting out, for example, ammonium sulfate, sodium chloride, barium carbonate, etc. can be used, and for precipitation treatment with an organic solvent, for example, methanol, ethanol, acetone, etc. can be used. It is preferable to carry out under the condition that the active ingredient in the product is not modified.

【0018】本発明の組成物をタケ類又はササ類から抽
出するにあたっては、該タケ類又はササ類の根茎部を使
用することが好ましい。根茎とはタケ類又はササ類の地
下茎を言うものであるが、本発明では植物組織の学術的
分類による名称の範囲にとらわれることはない。
When the composition of the present invention is extracted from bamboos or bamboo grasses, it is preferable to use the rhizome of the bamboos or bamboo grasses. The rhizome refers to the rhizome of bamboos or bamboo grasses, but in the present invention, it is not limited to the range of names according to the scientific classification of plant tissues.

【0019】また、本発明の物質を抽出し得るタケ類又
はササ類とは、例えば、多種多様に存在する以下の分類
の中から選択されるが、この限りではない。
The bamboos or bamboo grasses from which the substance of the present invention can be extracted are selected, for example, from the following various types, but are not limited thereto.

【0020】単軸型タケ類 1.マダケ属 モウソウチク、キッコウチク、マダケ、キンメイチク、
オウゴンチク、シポチク、コンシマダケ、キシマダケ、
カシロダケ、ハチク、クロチク、ウンモンチク、メグロ
チク、ゴマダケ、カブロチク、シハマチク、ホテイチ
ク、ギンメイハチク、シマホテイチク及びケイチキ 2.ナリヒラダケ属 ナリヒラダケ、ニッコウナリヒラ、ヤシャダケ、リクチ
ュウダケ及びビロウドナリヒラ 3.トウチク属 トウチク及びスズコナリヒラ 4.カンチク属 チゴカンチク及びシホウチク 5.オカメザサ属 オカメザサ連軸型タケ類 6.ホウライチク属 ホウライチク、ホウオウチク、ホウショウチク、スホウ
チク及びタイザンチクササ類 7.メダケ属 カンザンチク、タイメンチク、リュウキュウチク、メダ
ケ、ハガワリメダケ、ハコネダケ、アズマネザサ、ヒメ
シマダケ、ケネザサ、オシロマチク、アケボノザサ、カ
ムロザサ及びイヨスダレ 8.ササ属 ミヤコザサ、クマザサ、ヤダケ、ラッキョウチク、ネマ
ガリダケ、シャコタンチク及びキンタイザサ また、一般に知られるタケノコとはモウソウチクの地下
茎の芽子の肥大したものである。本発明でいうタケ及び
ササ類にはタケノコも包含される。
Single-axis bamboos 1. Pleurotus ostreatus, sardine, oyster mushroom,
Amberjack, Shipotiku, Astragalus, Kisimatake,
1. White oyster mushrooms, bee honey, black bee squirrels, unmonchik, yellow squirrels, sesame mushrooms, kabrochik, shihamachiku, hoteichiku, ginmeihachiku, shimahoteichiku and kechiki. 2. Pleurotus cornucopiae Pleurotus cornucopiae, Pleurotus cornucopiae, Pleurotus cornucopiae, Pleurotus cornucopiae, Pleurotus cornucopiae and P. mellifera Tochiku genus Touchiku and Suzukonarihira 4. 4. Citrus spp. Oxameza genus Oxamexasa axis-type bamboos 6. Bambusa multiplex genus Bambusa multiplex, Hououchiku, Houshouchiku, Suhouchiku and Taizanchiku bamboo grass 7. 7. Pleurotus genus Kanzantiku, Taimenchik, Ryukyuchiku, Medake, Hagarari medaka, Hakonedake, Azmanezasa, Himeshimatake, Kenezasa, Oshiromachiku, Akebonozasa, Kamuroza and Iyosare 8. Sasa genus Miyakosasa, Kumasasa, Bamboo shoots, Rakkyochiku, Nemagaritake, Pleurotus chinensis and Kintaisasa Also, the commonly known bamboo shoots are enlarged spores of the rhizomes of Mosouchi. Bamboo shoots are also included in the bamboos and bamboo grasses referred to in the present invention.

【0021】また、同種のタケ類又はササ類から抽出し
た組成物であっても、それらの生域により若干の抗腫瘍
活性のバラツキを認めた。これには、生育地の岩盤、土
壌、土壌中の細菌、温度、湿度、降雨量、立地条件(日
照時間、風当たり)、共生植物及び生域内に生息する動
物などがファクターとなっていると考えられ、北方及び
寒冷地に群生するタケ類が好ましい。特に東北地方のも
のが好適であり、岩盤中に含有される金属種及び濃度、
並びに土壌中の細菌の種及び量などが大きなファクター
となると考えられる。
Further, even in the composition extracted from the same type of bamboo or bamboo grass, some variations in antitumor activity were observed depending on their living areas. Factors considered to be this are rocks in the habitat, soil, bacteria in the soil, temperature, humidity, rainfall, location conditions (sunlight hours, wind), symbiotic plants, and animals living in the living area. Bamboo mushrooms that grow in the north and cold regions are preferable. In particular, those in the Tohoku region are suitable, and the metal species and concentration contained in the bedrock,
In addition, the species and amount of bacteria in the soil are considered to be a major factor.

【0022】本発明の組成物は、少なくともin vi
troにおいて抗腫瘍活性を有するものである。本発明
の組成物からなる抗腫瘍剤は、腫瘍細胞、特に白血病、
成人T細胞白血病由来の腫瘍細胞に対し顕著な活性を認
め、且つ薬剤の投与から効果(抗腫瘍活性)発現までの
応答性が特異的であり、作用機序が通常の抗腫瘍剤と異
なる様相を呈するものであった。
The compositions of the present invention are at least in vivo
It has antitumor activity in tro. The antitumor agent comprising the composition of the present invention is a tumor cell, particularly leukemia,
A mode in which a remarkable activity is observed against tumor cells derived from adult T-cell leukemia, and the response from the administration of the drug to the expression of the effect (antitumor activity) is specific, and the mechanism of action is different from that of conventional antitumor agents Was presented.

【0023】即ち、薬剤の投与後、その効果が確認でき
ない期間を有し、しかしある時点から強い殺細胞効果を
発現する。また、腫瘍細胞核の縮小が認められるもの
の、崩壊像がなく、従来の抗腫瘍剤に認められる風船状
細胞は殆ど見られない。
That is, after administration of the drug, there is a period in which its effect cannot be confirmed, but a strong cell killing effect is exhibited from a certain point. Moreover, although the tumor cell nucleus was reduced, there was no disintegration image, and balloon-like cells observed in conventional antitumor agents were hardly seen.

【0024】これらは、本発明の組成物による抗腫瘍剤
の作用機序が従来のものと異なる可能性を示すものであ
り、タンパク質又はRNAに対し作用することで抗腫瘍
活性が発現している可能性が推測される。
These indicate that the mechanism of action of the antitumor agent by the composition of the present invention may be different from the conventional ones, and antitumor activity is expressed by acting on protein or RNA. The possibility is estimated.

【0025】すなわち、本発明の組成物は腫瘍細胞のみ
ならず成人T細胞白血病のように、ウイルス感染した細
胞に対する殺細胞効果も期待できる。
That is, the composition of the present invention can be expected to have a cytocidal effect not only on tumor cells but also on virus-infected cells such as adult T-cell leukemia.

【0026】従って、本発明の組成物はB型肝炎、非A
非B型肝炎及びAIDSなど疾病に対して、抗ウイルス
剤として使用できる可能性がある。
Accordingly, the composition of the present invention comprises hepatitis B, non-A
It may be used as an antiviral agent against diseases such as non-hepatitis B and AIDS.

【0027】本組成物を、抗腫瘍剤として用いる場合に
は、任意の投与形態及び投与経路で行うことができる。
When the composition is used as an antitumor agent, it can be administered in any dosage form and administration route.

【0028】投与形態としては、例えば、錠剤、カプセ
ル及びシロップ等の形態が挙げられ、更に、薬理学的に
許容される賦形剤、助剤及び安定剤等を含有させても良
い。
The dosage form includes, for example, tablets, capsules, syrups and the like, and may further contain pharmacologically acceptable excipients, auxiliaries and stabilizers.

【0029】また、投与経路としては、皮下、筋肉及び
静脈等への注射、並びに経口投与等が挙げられるがこの
限りではない。
The route of administration includes, but is not limited to, subcutaneous injection, intramuscular injection, intravenous injection, and oral administration.

【0030】本発明の組成物の投与量としては、体重1
kg、1日当たり約0.001mg〜約10gを1〜6
回に分けて投与する。
The dose of the composition of the present invention is 1
1 to 6 kg, about 0.001 mg to about 10 g per day
Administer in divided doses.

【0031】しかしながら、前記投与量は、動物種(ヒ
トを含む)、年齢、病状及び薬剤感受性等によって異な
るため、前記範囲外の量を投与する場合も生じる。その
際は、当業者によって最適な投与量が設定されよう。
However, since the dose varies depending on the animal species (including human), age, medical condition, drug susceptibility, etc., the dose outside the above range may occur. In that case, a person skilled in the art will set the optimal dose.

【0032】以下、実施例により本発明を詳細に説明す
るが、本発明はこれに限定されるものではない。
Hereinafter, the present invention will be described in detail with reference to Examples, but the present invention is not limited thereto.

【0033】[0033]

【実施例】【Example】

[実施例1]タケノコ(タケ類)の根茎抽出液の調製 (1−1) 単軸型タケ類マダケ属モウソウチクの根に
密在している赤色の根茎を採取した。プレス機を用いて
圧砕し、圧搾液及び圧砕粒をガーゼにとり、これを搾る
ことでタケノコ根茎部圧搾液を得た。このタケノコ根茎
部圧搾液をろ紙(東洋ろ紙社)を用いてろ過すること
で、本発明の組成物を含有する無色粘調性の液体が得ら
れた。これをA液と命名した。A液のpHは約5.4の
酸性を呈した。
[Example 1] Preparation of Rhizome Extract of Bamboo Shoots (Bamboo) (1-1) Red rhizomes that were densely present in the roots of the uniaxial type Bamboo sp. It was crushed using a pressing machine, the squeezed liquid and the crushed granules were taken in gauze, and this was squeezed to obtain a bamboo shoot rhizome squeezed liquid. By filtering this bamboo shoot rhizome pressing liquid using a filter paper (Toyo Roshi Kaisha, Ltd.), a colorless viscous liquid containing the composition of the present invention was obtained. This was named Solution A. The pH of the liquid A exhibited an acidity of about 5.4.

【0034】本発明の組成物は酸性及びアルカリ性にお
いて水に可溶であるが、中性付近においては(A液を水
で希釈すると)濁りを生じた。
The composition of the present invention was soluble in water in acidity and alkalinity, but turbidity was generated in the vicinity of neutrality (when the solution A was diluted with water).

【0035】A液1.0mlに蒸留水9.0mlを加え
全量を10.0mlとした。この10倍希釈液1mlを
分取し、0.1N NaOH溶液を9.0ml加え全量
を10.0mlとした。この溶液の紫外部吸収を測定す
ると、240nm、278nm及び330nmに吸収が
観測された。同様に、前記10倍希釈液より1mlを分
取し、0.1N HCl溶液を9.0ml加え全量を1
0.0mlとした溶液の紫外部吸収を測定すると251
nm及び323nmに吸収が観測された。
Distilled water (9.0 ml) was added to the liquid (A) (1.0 ml) to make the total amount 10.0 ml. 1 ml of this 10-fold diluted solution was collected and 9.0 ml of 0.1N NaOH solution was added to make the total volume 10.0 ml. When the ultraviolet absorption of this solution was measured, absorption was observed at 240 nm, 278 nm and 330 nm. Similarly, 1 ml was taken from the 10-fold diluted solution, and 9.0 ml of 0.1N HCl solution was added to bring the total volume to 1
It was 251 when the ultraviolet absorption of the solution of 0.0 ml was measured.
Absorption was observed at nm and 323 nm.

【0036】A液のニンヒドリン反応は陽性であり、ゲ
ルろ過クロマトグラフィーによる平均分子量は約1万〜
約3万であった。
The ninhydrin reaction of the liquid A was positive, and the average molecular weight by gel filtration chromatography was about 10,000-
It was about 30,000.

【0037】(1−2) 単軸型タケ類マダケ属モウソ
ウチクの根に密在している指状根茎を3〜4cm採取
し、外側を被覆する繊維質の部分を除去した。内部に存
在していた白色の柔軟なストランドを得、収集した。こ
れらをプレス機を用いて圧砕し、圧搾液及び圧砕粒をガ
ーゼにとり、これを搾ることでタケノコ根茎部圧搾液を
得た。このタケノコ根茎部圧搾液をろ紙(東洋ろ紙社)
を用いて自然ろ過し、本発明の組成物を含有する無色粘
調性の液体を得、B液と命名した。
(1-2) The finger-shaped rhizomes closely packed in the roots of the uniaxial Bamboo genus Bamboo genus Mosouchi were collected at 3 to 4 cm, and the fibrous portion covering the outside was removed. The white flexible strands that were present inside were obtained and collected. These were crushed using a pressing machine, the squeezed liquid and the crushed granules were taken in gauze, and this was squeezed to obtain a bamboo shoot root squeezed liquid. This bamboo shoot rhizome squeezing liquid is a filter paper (Toyo Filter Paper Co., Ltd.)
Was naturally filtered to obtain a colorless viscous liquid containing the composition of the present invention, which was designated as solution B.

【0038】B液1.0mlに蒸留水9.0mlを加え
全量を10.0mlとした。この10倍希釈液1mlを
分取し、0.1N NaOH溶液を9.0ml加え全量
を10.0mlとした。この溶液の紫外部吸収を測定す
ると、275nm及び328nmに吸収が観測された。
同様に、前記10倍希釈液より1mlを分取し、0.1
N HCl溶液を9.0ml加え全量を10.0mlと
した溶液の紫外部吸収を測定すると250nm及び32
0nmに吸収が観測された。
Distilled water (9.0 ml) was added to the solution (B) (1.0 ml) to make the total amount 10.0 ml. 1 ml of this 10-fold diluted solution was collected and 9.0 ml of 0.1N NaOH solution was added to make the total volume 10.0 ml. When the ultraviolet absorption of this solution was measured, absorption was observed at 275 nm and 328 nm.
Similarly, 1 ml was taken from the 10-fold diluted solution,
The UV absorption of a solution in which 9.0 ml of N HCl solution was added to make the total volume 10.0 ml was 250 nm and 32.
Absorption was observed at 0 nm.

【0039】B液のニンヒドリン反応は陽性であり、ゲ
ルろ過クロマトグラフィーによる平均分子量は約1万〜
約3万であった。また、B液1mlを蒸発乾固すること
により約1mgの蒸発残留物が得られ、該残留物は、ベ
ンゼン及びクロロホルム等の有機溶剤に難溶であり、ア
ルコールに可溶であった。
The ninhydrin reaction of solution B was positive, and the average molecular weight by gel filtration chromatography was about 10,000-
It was about 30,000. In addition, about 1 mg of an evaporation residue was obtained by evaporating and drying 1 ml of the liquid B to dryness, and the residue was hardly soluble in organic solvents such as benzene and chloroform and soluble in alcohol.

【0040】[実施例2] ネマガリダケ根茎からのア
ルコール抽出による調製 (2−1)粉砕したササ属ネマガリダケ根茎33.64
gを1リットルの丸底フラスコに入れ、これに150m
lのエタノールを加えて、約3時間、水浴上で温時抽出
し、不溶分を濾別して黄色のエタノール溶液を得た。次
いで、この抽出溶液を減圧下に濃縮乾固し、得られた固
体残渣を少量のエタノールに温時に溶解し、適量の水を
加えて放置すると淡黄色の固体沈殿が折出した。この物
質は、ニンヒドリン反応陽性であり、メタノール及びエ
タノールに可溶であり、且つ水に難溶、温時可溶であ
り、pH4.8(水溶液)を呈し、また抗腫瘍活性を示
した。
[Example 2] Preparation by alcohol extraction from Rhododendron japonicus (2-1) Crushed Rhododendron japonicum rhizome 33.64
g in a 1 liter round bottom flask,
l of ethanol was added, and the mixture was extracted on a water bath for about 3 hours while warm, and the insoluble matter was filtered off to obtain a yellow ethanol solution. Next, the extracted solution was concentrated to dryness under reduced pressure, the obtained solid residue was dissolved in a small amount of ethanol at a warm time, an appropriate amount of water was added, and the mixture was left to stand, and a pale yellow solid precipitate came out. This substance was ninhydrin-positive, soluble in methanol and ethanol, sparingly soluble in water, soluble in warm water, exhibited pH 4.8 (aqueous solution), and exhibited antitumor activity.

【0041】さらに、エタノール抽出残渣を100ml
のメタノールで同様に3時間抽出し、濾過したのち、減
圧下濃縮乾固し、淡黄色固体を得た。この物質は、エタ
ノール抽出により得られたものと同様の物性及び生物学
的活性を示した。
Furthermore, 100 ml of the ethanol extraction residue was added.
Was similarly extracted with methanol for 3 hours, filtered and then concentrated to dryness under reduced pressure to obtain a pale yellow solid. This substance showed similar physical properties and biological activity to those obtained by ethanol extraction.

【0042】(2−2)粉砕したネマガリダケ根茎45
gを、上記(2−1)と同様にエタノール150ml、
次いでメタノール100mlで温時抽出した後、合併し
た抽出液を活性アルミナを充填したカラムに通し目的物
質を吸着した。pH4.0の塩酸で溶出し、溶出液を中
和し、減圧下で濃縮し蒸発乾固して粉末状の淡黄色固体
を得た。さらに、塩酸溶出液のアルミナにメタノールを
通すことによって、目的物質を回収した。総量約50m
gの淡黄色固体が得られ、この物質は上記(2−1)で
得られたものと同様の物性及び生物学的活性を示した。
(2-2) Crushed Pleurotus cornucopiae 45
g in the same manner as in the above (2-1), 150 ml of ethanol,
Then, after extraction with 100 ml of methanol at a warm temperature, the combined extract was passed through a column packed with activated alumina to adsorb the target substance. It was eluted with hydrochloric acid having a pH of 4.0, the eluate was neutralized, concentrated under reduced pressure and evaporated to dryness to obtain a powdery pale yellow solid. Furthermore, the target substance was recovered by passing methanol through alumina of a hydrochloric acid eluate. Total amount about 50m
g of a pale yellow solid was obtained, and this substance showed the same physical properties and biological activity as those obtained in the above (2-1).

【0043】[実施例3] 抗腫瘍活性の測定 (3−1)腫瘍細胞の培養 ヒトリンパ芽球白血病株化細胞株(成人T細胞白血病細
胞株;RPMI−8402株)又はマウス白血病細胞株
(L−1210)を非選択性培地(通常の培地)を用
い、通常の培養条件で6日間培養した。
[Example 3] Measurement of antitumor activity (3-1) Culture of tumor cells Human lymphoblastic leukemia cell line (adult T cell leukemia cell line; RPMI-8402 strain) or mouse leukemia cell line (L 1210) was cultivated for 6 days under normal culture conditions using a non-selective medium (normal medium).

【0044】(3−2)細胞数の調整方法 非選択性培地中に成人T細胞白血病細胞(RPMI−8
402)又はマウス白血病細胞(L−1210)の培養
液を添加し、細胞数を105 cell/mlに調整し
た。
(3-2) Method for adjusting cell number Adult T-cell leukemia cells (RPMI-8) in a non-selective medium.
402) or mouse leukemia cell (L-1210) culture medium was added to adjust the cell number to 10 5 cells / ml.

【0045】(3−3)抗腫瘍活性の測定−1 ミリポア社製フィルターで濾過滅菌したB液を0μl
(コントロール)、0.5μl、5μl、50μl及び
180μlずつ分取し、前述の成人T細胞白血病細胞培
養液5ml中へそれぞれ添加(投与)した。更に、蛍光
色素DAPを1μg/mlとなるように添加して、腫瘍
細胞の染色体を発色させた。続いて、24時間毎に、B
液及びDAPを含有する腫瘍細胞培養液から0.5ml
を分取し、蛍光顕微鏡によって5500倍に拡大した像
を動的観察装置(VTRモニター)を用いて連続的に記
録した。この記録画像より、腫瘍細胞の総数及び死亡数
を計測した。ここで腫瘍細胞の死亡数は、腫瘍細胞が次
の条件『細胞外への核の断片の放出』、『細胞融解』又
は『核物質の液状流出』にあてはまった際に『腫瘍細胞
の細胞死』とみなして計測した。
(3-3) Measurement of antitumor activity-1 0 μl of solution B sterilized by filtration with Millipore filter
(Control), 0.5 μl, 5 μl, 50 μl and 180 μl were collected and added (administered) to 5 ml of the above-mentioned adult T cell leukemia cell culture medium. Furthermore, the fluorescent dye DAP was added so as to be 1 μg / ml, and the chromosome of tumor cells was colored. Then, every 24 hours, B
0.5 ml from the tumor cell culture solution containing broth and DAP
Was collected, and images magnified 5500 times by a fluorescence microscope were continuously recorded using a dynamic observation device (VTR monitor). From this recorded image, the total number of tumor cells and the number of deaths were counted. Here, the number of deaths of tumor cells refers to "cell death of tumor cells" when the tumor cells meet the following conditions "release of nuclear fragments to the outside of the cell", "cell lysis" or "liquid outflow of nuclear material". It was considered and measured.

【0046】以上を6日間継続し、B液による抗腫瘍活
性を腫瘍細胞の殺細胞率及び総細胞数(増殖抑制率)と
して算出し、殺細胞率の経時変化を図1に、投与後6日
目における殺細胞率及び総細胞数(増殖抑制率)を図2
に示した。
The above procedure was continued for 6 days, and the antitumor activity of solution B was calculated as the tumor cell killing rate and the total cell number (growth inhibition rate). The time course of the cell killing rate is shown in FIG. Fig. 2 shows the cell killing rate and total cell number (growth suppression rate) on day 2.
It was shown to.

【0047】本動的観察法は、細胞形態をリアルタイム
で確認できるものであり、生理活性物質などが細胞損傷
する様子だけでなく、細胞の変化過程、ついては生理活
性物質の作用既序をも考察できるものである。
The present dynamic observation method is capable of confirming the cell morphology in real time, and considers not only the manner in which a physiologically active substance is damaged by a cell, but also the changing process of the cell, and the previous action of the physiologically active substance. It is possible.

【0048】本発明の組成物を投与した後の細胞形態の
変化としては、腫瘍細胞の崩壊像は見られないものの、
細胞の核は経時的に縮小し、細胞原形質は崩れていっ
た。一般的な抗癌剤に見られる、例えば、細胞の風船状
化のような、多種多様な細胞形態の変化は確認されなか
った。
Regarding the change in cell morphology after administration of the composition of the present invention, no image of tumor cell disintegration was observed,
The cell nuclei shrank over time, and the cytoplasm collapsed. A wide variety of changes in cell morphology, such as cell ballooning, found in common anticancer agents have not been confirmed.

【0049】(3−4)抗腫瘍活性の測定−2 濾過滅菌したA液より0μl(コントロール)、10μ
l、50μl及び150μlずつ分取し、前述の成人T
細胞白血病細胞培養液5ml中へそれぞれ添加した以外
は(3−3)と同様にして抗腫瘍活性を測定した。これ
より算出したA液の殺細胞率の経時変化を図3に示し
た。また、細胞形態の変化に関しても(3−3)と同様
の挙動が確認された。
(3-4) Measurement of antitumor activity-2 0 μl (control), 10 μl from solution A sterilized by filtration
1, 50 μl and 150 μl each are taken, and the adult T
Antitumor activity was measured in the same manner as in (3-3) except that each was added to 5 ml of cell leukemia cell culture medium. The time course of the cell killing rate of solution A calculated from this is shown in FIG. Also, regarding the change in cell morphology, the same behavior as in (3-3) was confirmed.

【0050】(3−5)抗腫瘍活性の測定−3 [実施例2]の(2−1)で得られたアルコール抽出物
(淡黄色固体)約1mgにTween−80 2滴を加
え、さらに滅菌水を加えて総量3mlとし、濾過滅菌
後、0μl(コントロール)、10μl、50μl及び
150μlずつ分取し、105 cell/mlの成人T
細胞白血病細胞(RPMI−8402)又はマウス白血
病細胞(L−1210)培養液5ml中へ添加し、(3
−3)と同様にして抗腫瘍活性を測定した。これより算
出した本発明物質の殺細胞率の経時変化をそれぞれ図4
及び図5に示した。図から明らかなように、成人T細胞
白血病細胞に対しては、150μlで1日目に約100
%、50μlで4日目に約90%の殺細胞効果が得ら
れ、またL−1210細胞に対しては、150μlで1
日目に約100%、50μlで70時間目に約90%の
殺細胞効果が得られた。
(3-5) Measurement of antitumor activity-3 Two drops of Tween-80 were added to about 1 mg of the alcohol extract (pale yellow solid) obtained in (2-1) of [Example 2], and further added. Sterilized water was added to make a total volume of 3 ml, and after filter sterilization, 0 μl (control), 10 μl, 50 μl, and 150 μl were collected, and 10 5 cell / ml of adult T
Cell leukemia cells (RPMI-8402) or mouse leukemia cells (L-1210) were added to 5 ml of a culture solution,
The antitumor activity was measured in the same manner as in -3). The time course of the cell killing rate of the substance of the present invention calculated from this is shown in FIG.
And shown in FIG. As is clear from the figure, for adult T-cell leukemia cells, 150 μl gave about 100
%, About 90% of the cell killing effect was obtained on the 4th day with 50 μl, and with L-1210 cells, 1 μl was obtained with 150 μl.
A cell killing effect of about 100% on the day and about 90% at 70 hours with 50 μl was obtained.

【0051】また、細胞形態の変化に関しても(3−
3)と同様の挙動が確認された。
Regarding the change of cell morphology (3-
The same behavior as 3) was confirmed.

【0052】なお、[実施例2]の(2−2)で得られ
た淡黄色固体についても同様にテストした結果、両腫瘍
細胞に対し同様の殺細胞活性が確認された。
The same test was performed on the pale yellow solid obtained in (2-2) of [Example 2], and the same cell killing activity was confirmed for both tumor cells.

【0053】[実施例4] 本発明による抗腫瘍剤組成
物の製剤例 [実施例1]で得たB液100mgを10mlアンプル
管に入れ、窒素封入を施した後、アンプルを閉じた。こ
れより、10本のアンプルが作成できた。
Example 4 Preparation Example of Antitumor Agent Composition According to the Present Invention 100 mg of the solution B obtained in [Example 1] was placed in a 10 ml ampoule tube, and nitrogen was sealed therein, and then the ampoule was closed. From this, 10 ampoules were created.

【0054】[0054]

【発明の効果】腫瘍細胞、特に、白血病、成人T細胞白
血病細胞に対して顕著な殺細胞活性及び/又は増殖抑制
性を示し、抗腫瘍剤として有用である。
INDUSTRIAL APPLICABILITY Tumor cells, particularly leukemia and adult T-cell leukemia cells, exhibit remarkable cytocidal activity and / or growth inhibitory activity and are useful as antitumor agents.

【図面の簡単な説明】[Brief description of drawings]

【図1】成人T細胞白血病細胞(RPMI−8402)
に対する本発明の組成物(B液)の殺腫瘍細胞率の経時
変化を示す。50μl以上添加した系において、投与後
4日目から顕著な細胞障害性が認められる。
FIG. 1 Adult T-cell leukemia cells (RPMI-8402)
5 shows the time-dependent change in the tumoricidal cell rate of the composition of the present invention (solution B) against. In the system added with 50 μl or more, remarkable cytotoxicity is observed from the 4th day after administration.

【図2】成人T細胞白血病細胞(RPMI−8402)
に対する投与後6日目のB液の各濃度における抗腫瘍活
性。図中、白棒は総細胞数(右縦軸)、黒棒は殺細胞率
(左縦軸)を表す。50μl以上添加した系において顕
著な細胞障害性が認められる。また0.5及び5μlを
添加した系においても総細胞数の減少(腫瘍細胞の増殖
抑制性)が認められる。
FIG. 2 Adult T-cell leukemia cells (RPMI-8402)
Antitumor activity at each concentration of solution B on day 6 after administration to. In the figure, the white bar represents the total cell number (right vertical axis), and the black bar represents the cell killing rate (left vertical axis). Remarkable cytotoxicity is observed in the system added with 50 μl or more. In addition, a decrease in total cell number (inhibition of tumor cell growth) is also observed in the system containing 0.5 and 5 μl.

【図3】成人T細胞白血病細胞(RPMI−8402)
に対する本発明の組成物(A液)の殺腫瘍細胞率の経時
変化を示す。150μl以上添加した系において、投与
後4日目から顕著な細胞障害性が認められる。
FIG. 3 Adult T-cell leukemia cells (RPMI-8402)
5 shows the time-dependent change in the tumoricidal cell rate of the composition of the present invention (Solution A). In the system added with 150 μl or more, remarkable cytotoxicity is observed from the 4th day after administration.

【図4】マウス白血病細胞株(L−1210)に対する
本発明の組成物([実施例2]の(2−1)のアルコー
ル抽出物)の殺腫瘍細胞率の経時変化を示す。
FIG. 4 shows the time course of the tumoricidal cell rate of the composition of the present invention (alcohol extract of (2-1) of [Example 2]) against mouse leukemia cell line (L-1210).

【図5】成人T細胞白血病細胞(RPMI−8402)
に対する本発明の組成物([実施例2]の(2−1)の
アルコール抽出物)の殺腫瘍細胞率の経時変化を示す。
FIG. 5: Adult T-cell leukemia cells (RPMI-8402)
2 shows the time-dependent change in the tumoricidal cell rate of the composition of the present invention (alcohol extract of (2-1) in [Example 2]) against.

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 タケ又はササ類に属する植物より抽出さ
れ得る抗腫瘍剤組成物であって、該組成物がニンヒドリ
ン反応陽性、ゲルろ過クロマトグラフィーによる平均分
子量が約1万〜約3万、約4.0〜約7.0のpHを呈
し、ベンゼン及びクロロホルム等の有機溶剤に難溶、ア
ルコールに可溶、酸性もしくはアルカリ性の水溶液に可
溶であり、該水溶液中で紫外可視吸収を250nm付近
(酸性)及び280nm付近(アルカリ性)に有するこ
とを特徴とする抗腫瘍剤組成物。
1. An antitumor agent composition which can be extracted from a plant belonging to bamboo or bamboo grass, wherein the composition has a positive ninhydrin reaction and an average molecular weight by gel filtration chromatography of about 10,000 to about 30,000. It has a pH of 4.0 to about 7.0, is poorly soluble in organic solvents such as benzene and chloroform, soluble in alcohol, soluble in acidic or alkaline aqueous solution, and has an ultraviolet-visible absorption in the aqueous solution of around 250 nm. An antitumor agent composition having (acidic) and around 280 nm (alkaline).
【請求項2】 前記タケ又はササ類に属する植物が、マ
ダケ属モウソウチク、キッコウチク、マダケ、キンメイ
チク、オウゴンチク、シポチク、コンシマダケ、キシマ
ダケ、カシロダケ、ハチク、クロチク、ウンモンチク、
メグロチク、ゴマダケ、カブロチク、シハマチク、ホテ
イチク、ギンメイハチク、シマホテイチク及びケイチ
キ、並びにナリヒラダケ属ナリヒラダケ、ニッコウナリ
ヒラ、ヤシャダケ、リクチュウダケ及びビロウドナリヒ
ラ、並びにトウチク属トウチク及びスズコナリヒラ、並
びにカンチク属チゴカンチク及びシホウチク、並びにオ
カメザサ属オカメザサ、並びにホウライチク属ホウライ
チク、ホウオウチク、ホウショウチク、スホウチク及び
タイザンチク、並びにササ類がメダケ属カンザンチク、
タイメンチク、リュウキュウチク、メダケ、ハガワリメ
ダケ、ハコネダケ、アズマネザサ、ヒメシマダケ、ケネ
ザサ、オシロマチク、アケボノザサ、カムロザサ及びイ
ヨスダレ、並びにササ属ミヤコザサ、クマザサ、ヤダ
ケ、ラッキョウチク、ネマガリダケ、シャコタンチク及
びキンタイザサからなる群から選択される請求項1の抗
腫瘍剤組成物。
2. The plant belonging to the bamboo or sasa genus is moss of the genus Physcomitrella patens, Kikkochiku, Madake, Kinmeichiku, Ogongonchi, Shipotchiku, Konshimadake, Kisimatake, Kakurodoke, Hachiku, Kurochiku, Unmonchiku,
Yellow-tailed moss, sycamore, cabrochik, shihamachi, hoteichiku, chinmeihachiku, shimahoteichiku and kechiki, as well as genus Narihidake, moss moss, moss moss, citrus moss , And porpoise genus porphyra, porphyra cinerea, phoenix vulgaris, crocodile and cypress, and the genus Physcomitrium spp.
Taimenchiku, Ryukyuchiku, Medake, Hagariwamedake, Hazelnut mushroom, Azmanezasa, Himesimatake, Kenezasa, Oshiromachiku, Akebonosasa, Kamuroza and Iyosudare, and selected from the group of the genus Lactarius, Kamaza, Yadachi, and Ryakugaku, Rakugachi The antitumor agent composition according to claim 1.
JP6325622A 1993-12-27 1994-12-27 Antitumor agent composition Pending JPH07300424A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP6325622A JPH07300424A (en) 1993-12-27 1994-12-27 Antitumor agent composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP5-331169 1993-12-27
JP33116993 1993-12-27
JP6325622A JPH07300424A (en) 1993-12-27 1994-12-27 Antitumor agent composition

Publications (1)

Publication Number Publication Date
JPH07300424A true JPH07300424A (en) 1995-11-14

Family

ID=26571891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6325622A Pending JPH07300424A (en) 1993-12-27 1994-12-27 Antitumor agent composition

Country Status (1)

Country Link
JP (1) JPH07300424A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413208A1 (en) * 2002-10-24 2004-04-28 Adaptgen Pharmaceutical Co., Ltd. Health food and antitumor agent
JP2005320261A (en) * 2004-05-06 2005-11-17 Hoodo:Kk Carcinostatic agent
JP2006515007A (en) * 2003-03-27 2006-05-18 ユニジェン インク. Composition containing bamboo extract and compounds isolated therefrom, showing therapeutic and prophylactic activity for inflammatory and blood circulation diseases
WO2013069821A1 (en) * 2011-11-10 2013-05-16 Michio Tani Malignant tumor treatment agent and food and drink including same

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413208A1 (en) * 2002-10-24 2004-04-28 Adaptgen Pharmaceutical Co., Ltd. Health food and antitumor agent
JP2006515007A (en) * 2003-03-27 2006-05-18 ユニジェン インク. Composition containing bamboo extract and compounds isolated therefrom, showing therapeutic and prophylactic activity for inflammatory and blood circulation diseases
JP4684893B2 (en) * 2003-03-27 2011-05-18 ユニジェン インク. Bamboo extract showing a therapeutic and preventive activity for inflammatory and blood circulation diseases and a composition containing a compound isolated therefrom
JP2005320261A (en) * 2004-05-06 2005-11-17 Hoodo:Kk Carcinostatic agent
WO2013069821A1 (en) * 2011-11-10 2013-05-16 Michio Tani Malignant tumor treatment agent and food and drink including same
JP2013103886A (en) * 2011-11-10 2013-05-30 Michishi Tani Malignant tumor treatment agent, and food/drink containing the same

Similar Documents

Publication Publication Date Title
EP1507544B1 (en) Use of a fraction having anti-cancer activity, isolated from leaves and stems of ginseng (Panax)
DE69636343T2 (en) USE OF GLU-TRP DIPEPTIDES FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING VARIOUS VASCULAR REJECTION-ASSOCIATED DISEASES
DE60300011T2 (en) Perindopril salt and medicinal product containing it
JP2003238432A (en) Hyaluronic acid acuumulation-accelerating agent
CN106794210A (en) Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition
JP6600626B2 (en) Methods for obtaining plant extracts and related compositions
DE2710327C3 (en) Use of benzaldehyde
CN101020715B (en) Process of extracting and preparing deer nerve growth factor (DEER NGF)
CN1706264A (en) Chinese goldthread flower and/or leaf tea
DE102015120353A1 (en) Pharmaceutical composition for the support of chemotherapy drugs and their use
US4806659A (en) Tannin compounds
US20170143748A1 (en) Anti-tumor pharmaceutical application of pentacyclic triterpene saponin compounds of szechuan melandium root
CN103435692A (en) Application of ginseng glycoprotein in medicaments and health-care foods for treating senile dementia
JPH07300424A (en) Antitumor agent composition
KR100838113B1 (en) Cultivation method of phellinus linteus including edible gold dust and its phellinus linteus
CN102488779A (en) Application of extract of Antlerpilose grass
KR102264494B1 (en) Composition for preventing, improving or treating osteoarthritis using mixture of natural ingredients
WO2008009655B1 (en) Medical use of n-phenylpropenoyl-amino acid derivatives and related compounds
KR20030001659A (en) Hepatoprotective extract derived from Protaetia brevitarsis and its use
JPH04300836A (en) Hepatic dysfunction preventive agent and functional food having preventive action on hepatic dysfunction
RU2710261C1 (en) Method for complex treatment fresh fruits of hawthorn
CN102813659A (en) Use of 20alpha-dimethylamino-2alpha-hydroxy-3beta-tiropramide-5alpha-pregnane
DE2639410C2 (en) Polypeptide VI-7501 with anti-tumor activity
CH640865A5 (en) GLYCOPROTEIDE OF HUMAN URINE, METHOD FOR THE PRODUCTION THEREOF AND MEANS FOR COMBATING LEUKOCYTOPENIA.
CN110272508A (en) A kind of preparation method and its usage of Fructus Aurantii polyoses extract